Quanterix (QTRX) AD Offering Gets FDA's Breakthrough Device Tag [Yahoo! Finance]
Quanterix Corporation (QTRX)
US:NASDAQ Investor Relations:
ir.quanterix.com/investor-relations
Company Research
Source: Yahoo! Finance
Breakthrough Device designation to its Simoa phospho-Tau 217 (p-Tau 217) blood test for Alzheimer's Disease (AD). The company claims that the p-Tau 217 biomarker is a highly promising tool for accurately diagnosing amyloid pathology. The FDA's Breakthrough Device designation is granted to products that have the potential to offer superior diagnosis of life-threatening diseases with an unmet medical need. Transforming Alzheimer's Diagnostics Traditional methods for assessing AD, such as positron emission tomography scans and lumbar punctures, are invasive and often inaccessible. With early detection being pivotal in improving patient outcomes, the availability of a sensitive blood test for AD could significantly impact patient care. Quanterix's blood-based biomarker test offers a noninvasive alternative, potentially revolutionizing how AD is diagnosed and managed. The NIA-AA criteria identifies p-Tau 217 as the only plasma biomarker appropriate for accurately diagnosing amyloid
Show less
Read more
Impact Snapshot
Event Time:
QTRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QTRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QTRX alerts
High impacting Quanterix Corporation news events
Weekly update
A roundup of the hottest topics
QTRX
News
- Investing in Quanterix (NASDAQ:QTRX) a year ago would have delivered you a 111% gain [Yahoo! Finance]Yahoo! Finance
- Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer's Disease Testing Infrastructure [Yahoo! Finance]Yahoo! Finance
- Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer’s Disease Testing InfrastructureBusiness Wire
- Quanterix Co. (NASDAQ: QTRX) had its price target raised by analysts at Scotiabank from $30.00 to $32.00. They now have a "sector outperform" rating on the stock.MarketBeat
- Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer's Disease [Yahoo! Finance]Yahoo! Finance
QTRX
Earnings
- 2/29/24 - Miss
QTRX
Sec Filings
- 4/17/24 - Form 4
- 4/15/24 - Form ARS
- 4/15/24 - Form DEF
- QTRX's page on the SEC website